Valuation: Compugen Ltd.

Market Cap 22Cr 0 19Cr 18Cr 17Cr 31Cr 2.1TCr 31Cr 219.59Cr 85Cr 1.08TCr 82Cr 80Cr 3.45TCr P/E 2026 *
-8.25x
P/E 2027 * -8.37x
Enterprise Value 22Cr 0 19Cr 18Cr 17Cr 31Cr 2.1TCr 31Cr 219.59Cr 85Cr 1.08TCr 82Cr 80Cr 3.45TCr EV / Sales 2026 *
23.7x
EV / Sales 2027 * 28.2x
Free-Float
99.84%
Yield 2026 *
-
Yield 2027 * -
1 week+2.22%
1 month-7.62%
3 months+4.17%
6 months+3.99%
Current year+55.75%
1 week 717.5
Extreme 717.5
733.2
1 month 710
Extreme 710
796
Current year 485.2
Extreme 485.2
924
1 year 460.8
Extreme 460.8
924
3 years 208.1
Extreme 208.1
1,175
5 years 208.1
Extreme 208.1
2,358
10 years 208.1
Extreme 208.1
6,766
Manager TitleAgeSince
Chief Executive Officer - 23/09/2025
Director of Finance/CFO 42 15/08/2024
Chief Operating Officer 49 01/01/2024
Director TitleAgeSince
Chairman 59 23/09/2025
Director/Board Member 59 11/06/2018
Director/Board Member 70 11/06/2018
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+2.22% - - 22Cr
+4.16%+3.04%+49.37%+94.17% 7.42TCr
-3.11%-3.53%+20.19%+81.44% 5.74TCr
+0.89%-0.63%+2.17%+36.19% 4.76TCr
+0.36%+0.81%+342.39%+742.40% 4.43TCr
-0.96%-4.50%+24.96%+35.38% 4.25TCr
-0.20%-0.77%+4.13%+105.50% 4.07TCr
-0.54%+2.93%+9.31%+50.41% 3.1TCr
-2.68%+2.92%+29.33%+22.72% 2.85TCr
+0.05%-1.64%-8.14%-11.37% 2.43TCr
Average -0.20%-0.59%+52.63%+128.54% 4.34TCr
Weighted average by Cap. +0.12%-0.84%+56.96%+138.26%

Financials

2026 *2027 *
Net sales 92.39L 0 82.09L 76.62L 69.83L 1.32Cr 89Cr 1.33Cr 9.27Cr 3.59Cr 45Cr 3.47Cr 3.39Cr 145.72Cr 77.5L 0 68.86L 64.27L 58.58L 1.1Cr 75Cr 1.12Cr 7.78Cr 3.01Cr 38Cr 2.91Cr 2.85Cr 122.23Cr
Net income -2.65Cr -0 -2.35Cr -2.19Cr -2Cr -3.77Cr -254.41Cr -3.81Cr -27Cr -10Cr -130.06Cr -9.94Cr -9.72Cr -417.41Cr -2.7Cr -0 -2.39Cr -2.23Cr -2.04Cr -3.84Cr -259.08Cr -3.88Cr -27Cr -10Cr -132.45Cr -10Cr -9.9Cr -425.07Cr
Net Debt - -
Logo Compugen Ltd.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Employees
75
Date Price Change Volume
01/26/01 ILA 728.90 0.00% 16,931
30/26/30 ILA 728.90 +0.03% 2,789
29/26/29 ILA 728.70 -0.42% 17,823
28/26/28 ILA 731.80 +2.62% 27,121
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.310USD
Average target price
4.600USD
Spread / Average Target
+99.13%

Quarterly revenue - Rate of surprise